Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions

Pharmacological Research

Volumn 97, Issue , 2015, Pages 122-130

  Della Latta, Veronica ^a,b   Cecchettini, A ^a,c   Del Ry, S ^a   Morales, M A ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Animal models; Bleomycin (BLM); Extracellular matrix (ECM); Idiopathic pulmonary fibrosis (IPF); Pulmonary fibrosis; Transforming growth factor beta (TGF )

Indexed keywords

AM 966; ANTICOAGULANT AGENT; ANTIFLAMMIN; ANTIFLAMMIN 1; ANTIINFLAMMATORY AGENT; BERBERINE; COLLAGEN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; GAMMA INTERFERON; GEFITINIB; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LYSOPHOSPHATIDIC ACID; LYSYL OXIDASE LIKE 2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLSIDOMINE; NINTEDANIB; PIRFENIDONE; PROTEIN LYSINE 6 OXIDASE; QUERCETIN; SIMTUZUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL MIGRATION; COLLAGEN SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL ANIMAL; FIBROBLAST; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MACROPHAGE ACTIVATION; NEUTROPHIL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; LUNG FIBROSIS; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; HUMANS; PULMONARY FIBROSIS;

EID: 84930678119     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.04.012     Document Type: Review

References (67)

1. H. Umezawa, Y. Suhara, T. Takita, and K. Maeda Purification of bleomycin J. Antibiot. 19 1966 210 215
2. T. Takita, Y. Muraoka, T. Nakatani, A. Fuji, Y. Iitaka, and Y. Umezawa Metal-complex of bleomycin and its implication for the mechanism of bleomycin action J. Antibiot. 31 1978 1073 1077
3. C.A. Claussen, and E.C. Long Nucleic acid recognition by metal complexes of bleomycin Chem. Rev. 99 1999 2797 2816
4. A. Moeller, J.C. Rodriguez-Lecompte, L. Wang, J. Gauldie, and M. Kolb Models of pulmonary fibrosis Drug Discov. Today Dis. Models 3 2006 243 249
5. D.M. Walters, and S.R. Kleeberger Mouse models of bleomycin-induced pulmonary fibrosis Curr. Protoc. Pharmacol. 5 46 2008 1 17
6. U. Galm, M.H. Hager, S.G. Van Lanen, J. Ju, J.S. Thorson, and B. Shen Antitumor antibiotics: bleomycin, enediynes, and mitomycin Chem. Rev. 105 2005 739 758
7. L.M. Mir, O. Tounekti, and S. Orlowski Bleomycin: revival of an old drug Gen. Pharmacol. 27 1996 745 748
8. J. Hay, S. Shahzeidi, and G. Laurent Mechanisms of bleomycin-induced lung damage Arch. Toxicol. 65 1991 81 94
9. A.H. Limper Chemotherapy-induced lung disease Clin. Chest Med. 25 2004 53 64
10. E. Azambujaa, J.F. Flecka, R.G. Batistab, and S.S. Menna Barretoc Bleomycin lung toxicity: who are the patients with increased risk? Pulm. Pharmacol. Ther. 18 2005 363 366
11. A.J. Fyfe, and P. McKay Toxicities associated with bleomycin J. R. Coll. Physicians Edinb. 40 2010 213 215
12. ATS/ERS American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the idiopathic interstitial pneumonias Am. J. Respir. Crit. Care Med. 165 2001 277 304
13. American Thoracic Society Documents An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am. J. Respir. Crit. Care Med. 183 2011 788 824
14. K.R. Flaherty, J.A. Mumford, S. Murray, E.A. Kazerooni, B.H. Gross, and T.V. Colb Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia Am. J. Respir. Crit. Care Med. 168 2003 543 548
15. N.R. Grande, M.N.D. Peão, C.M. de Sá, and A.P. Águas Lung fibrosis induced by bleomycin: structural changes and overview of recent advances Scanning Microsc. 12 1998 487 494
16. S. Sleijfer Bleomycin-induced pneumonitis Chest 120 2001 617 624
17. R.M. Burger, J. Peisach, and S.B. Horwitz Activated bleomycin A transient complex of drug, iron, and oxygen that degrades DNA J. Biol. Chem. 256 1981 11636 11644
18. R.M. Burger, J. Peisach, and S.B. Horwitz Mechanism of bleomycin action: in vitro studies Life Sci. 28 1981 715 727
19. S. Omoto, T. Takita, K. Maeda, and H. Umezawa The structure of the sugar moiety of bleomycin A2 J. Antibiot. 25 1972 752 754
20. L.F. Povirk, Y.H. Han, and R.J. Steighner Structure of bleomycin-induced DNA double-strand breaks: predominance of blunt ends and single-base 5′ extensions Biochemistry 28 1989 5808 5814
21. S.M. Hecht Bleomycin: new perspectives on the mechanism of action J. Nat. Prod. 63 2000 158 168
22. S. Uesugi, T. Shida, M. Ikehara, Y. Kobayashi, and Y. Kyogoku Identification of oligonucleotide fragments produced in a strand scission reaction of the d(C-G-C-G-C-G) duplex by bleomycin Nucleic Acids Res. 12 1984 1581 1592
23. C.K. Mirabelli, A. Ting, C.H. Huang, S. Mong, and S.T. Crooke Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage Cancer Res. 42 1982 2779 2785
24. D. Brömme, A.B. Rossi, S.P. Smeekens, D.C. Anderson, and D.G. Payan Human bleomycin hydrolase: molecular cloning, sequencing, functional expression, and enzymatic characterization Biochemistry 35 1996 6706 6714
25. P.A. O'Farrell, F. Gonzalez, W. Zheng, S.A. Johnston, and L. Joshua-Tor Crystal structure of human bleomycin hydrolase, a self-compartmentalizing cysteine protease Structure 7 1999 619 627
26. R. Rafii, M.M. Juarez, T.E. Albertson, and A.L. Chan A review of current and novel therapies for idiopathic pulmonary fibrosis J. Thorac. Dis. 5 2013 48 73
27. B.B. Moore, and C.M. Hogaboam Murine models of pulmonary fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 294 2008 152 160
28. M.A. Mouratis, and V. Aidinis Modeling pulmonary fibrosis with bleomycin Curr. Opin. Pulm. Med. 17 2011 355 361
29. M. Molina-Molina, J. Pereda, and A. Xaubet Experimental models for the study of pulmonary fibrosis: current usefulness and future promise Arch. Bronconeumol. 43 9 2007 501 507
30. A.L. Degryse, H. Tanjore, X.C. Xu, V.V. Polosukhin, B.R. Jones, and F.B. McMahon Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 299 2010 442 452
31. M.A. Malouf, P. Hopkins, G. Snell, and A.R. Glanville An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis Respirology 16 2011 776 783
32. W. Liu, J. Wan, J.Z. Han, C. Li, D.D. Feng, and S.J. Yue Antiflammin-1 attenuates bleomycin-induced pulmonary fibrosis in mice Respir. Res. 14 2013 1 11
33. A. Datta, C.J. Scotton, and R.C. Chambers Novel therapeutic approaches for pulmonary fibrosis Br. J. Pharmacol. 163 2011 141 172
34. C. Jakubzick, S.L. Kunkel, R.K. Puri, and C.M. Hogaboam Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis Immunol. Res. 30 2004 339 349
35. R.M. Du Bois Strategies for treating idiopathic pulmonary fibrosis Nat. Rev. Drug Discov. 9 2010 129 140
36. S. Park, and E.J. Lee Recent advances in idiopathic pulmonary fibrosis Tuberc. Respir. Dis. 74 2013 1 6
37. J.R. Covvey, and E.E. Mancl Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis Ann. Pharmacother. 48 2014 1611 1619
38. D. Saleh, K. Furukawa, M.S. Tsao, A. Maghazachi, B. Corrin, and M. Yanagisawa Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines Am. J. Respir. Cell Mol. Biol. 16 1997 187 193
39. A.M. Tager, P. LaCamera, B.S. Shea, G.S. Campanella, M. Selman, and Z. Zhao The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat. Med. 14 2008 45 54
40. M. Funke, Z. Zhao, Y. Xu, J. Chun, and A.M. Tager The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury Am. J. Respir. Cell Mol. Biol. 46 2012 355 364
41. N. Ahluwalia, B.S. Shea, and A.M. Tager New therapeutic targets in idiopathic pulmonary fibrosis aiming to rein in runaway wound-healing responses Am. J. Respir. Crit. Care Med. 190 2014 867 878
42. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, R.A. Bundey, and P.C. Prodanovich A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model Br. J. Pharmacol. 160 2010 1699 1713
43. Y. Bei, T. Hua-Huy, S. Duong-Quy, V.H. Nguyen, W. Chen, and C. Nicco Long-term treatment with fasudil improves bleomycin-induced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation Pulm. Pharmacol. Ther. 26 2013 635 643
44. V. Barry-Hamilton, R. Spangler, D. Marshall, S. McCauley, H.M. Rodriguez, and M. Oyasu Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment Nat. Med. 16 2010 1009 1017
45. T. Kilic, H. Parlakpinar, A. Polat, E. Taslidere, N. Vardi, and E. Sarihan Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats Inflammation 2014 10.1007/s10753-014-9841-1
46. R. Vema, L. Kushwah, D. Gohel, M. Patel, T. Marvania, and S. Balakrishnan Evaluating the ameliorative potential of Quercetin against the bleomycin-induced pulmonary fibrosis in wistar rats Pulm. Med. 2013 (Article ID 921724)
47. P. Chitra, G. Saiprasad, R. Manikandan, and G. Sudhandiran Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-kB dependant TGF-β activation: a biphasic experimental study Toxicol. Lett. 219 2013 178 193
48. B. Zhu, A.Q. Ma, L. Yang, and X.M. Dang Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway Int. J. Mol. Sci. 14 2013 24476 24491
49. H.I. Adamali, and T.M. Maher Current and novel drug therapies for idiopathic pulmonary fibrosis Drug Des. Dev. Ther. 6 2012 261 272
50. N.J. Lomas, K.L. Watts, K.M. Akram, N.R. Forsyth, and M.A. Spiteri Idiopathic pulmonary fibrosis: immunohistochemical analysis provides fresh insights into lung tissue remodeling with implications for novel prognostic markers Int. J. Clin. Exp. Pathol. 5 2012 58 71
51. K. Hisatomi, H. Mukae, N. Sakamoto, Y. Ishimatsu, T. Kakugawa, and S. Hara Pirfenidone inhibits TGF-β1-induced overexpression of collagen type I and heat shock protein 47 in A549 cells BMC Pulm. Med. 12 2012 24
52. B.C. Willis, and Z. Borok TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease Am. J. Physiol. Lung Cell. Mol. Physiol. 293 2007 525 534
53. T. Chen, H. Nieb, X. Gaoa, J. Yanga, J. Pua, and Z. Chena Epithelial-mesenchymal transition involved in pulmonary fibrosis induced by multi-walled carbon nanotubes via TGF-beta/Smad signaling pathway Toxicol. Lett. 226 2014 150 162
54. A. Leask, and D.J. Abraham TGF-β signaling and the fibrotic response FASEB J. 18 2004 816 827
55. Y. Ozawa, T. Suda, T. Naito, N. Enomoto, D. Hashimoto, and T. Fujisawa Cumulative incidence of and predictive factors for lung cancer in IPF Respirology 14 2009 723 728
56. K.R. Cutroneo, S.L. White, S.H. Phan, and H.P. Ehrlich Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression J. Cell. Physiol. 211 2007 585 589
57. A. Biernacka, M. Dobaczewski, and N.G. Frangogiannis TGF-β signaling in fibrosis Growth Factors Early Online 2011 1 7
58. P. Wang, Y. Wang, X. Nie, C. Braïni, R. Bai, and C. Chen Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease Fibrogenesis Tissue Repair 4 2011 1 10
59. M. Liang, J. Wang, H. Chu, X. Zhu, H. He, and Q. Liu Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis Mediat. Inflamm. 2013 (Article ID 209179)
60. S. Fichtner-Feigl, W. Strober, K. Kawakami, R.K. Puri, and A. Kitani IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis Nat. Med. 12 2006 99 106
61. Y. Ishii, S. Fujimoto, and T. Fukuda Gefitinib prevents bleomycin-induced lung fibrosis in mice Am. J. Respir. Crit. Care Med. 174 2006 550 556
62. P1 Wang, Q. Tian, Z.X. Liang, Z. Yang, S.F. Xu, and J.P. Sun Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin Chin. Med. J. (Engl.) 123 2010 2259 2264
63. T.E. King Jr., W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, and M.K. Glassberg A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2083 2092
64. M. Inomata, K. Kamio, A. Azuma, K. Matsuda, N. Kokuho, and Y. Miura Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis Respir. Res. 15 2014 16
65. L. Richeldi, U. Costabel, M. Selman, D.S. Kim, D.M. Hansell, and A.G. Nicholson Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N. Engl. J. Med. 365 2011 1079 1087
66. L. Richeldi, R.M. Du Bois, G. Raghu, A. Azuma, K.K. Brown, and U. Costabel Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N. Engl. J. Med. 2014 10.1056/NEJMoa1402584
67. L. Wollin, I. Maillet, V. Quesniaux, A. Holweg, and B. Ryffel Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis J. Pharmacol. Exp. Ther. 349 May 2014 209 220